Sweden's Modus Therapeutics reports bigger Q4 loss

Modus Therapeutics Holding AB

25/02/2026 07:12

Overview

Swedish biotech firm's Q4 loss after tax was SEK 5.32 mln

Company initiated Part 2 of Phase IIa CKD anemia study in Q4 2025

Company strengthened financial position with oversubscribed rights issue

Outlook

Modus expects funding to support operations through Phase IIa study readout by year-end 2026

Company focuses on disciplined study execution and Phase IIa readout preparation in 2026

Modus continues structured partnering efforts in sepsis

Result Drivers

CLINICAL EXECUTION - Modus completed Part 1 and initiated Part 2 of Phase IIa CKD anemia study, focusing on proof-of-concept

FINANCIAL STRENGTHENING - Oversubscribed rights issue improved financial position, supporting continued study execution

PRECLINICAL DATA - New data from Brescia collaboration reinforced sevuparin's potential in CKD with anemia

Company press release: ID:nMFN7F19HW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-SEK 0.04
Q4 Net Income
-SEK 5.32 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)